Rexahn names new CMO
This article was originally published in Scrip
Executive Summary
Rexahn Pharmaceuticals, a clinical stage biopharmaceutical company developing therapeutics for the treatment of cancer, has named Dr Ely Benaim chief medical officer. In this role, Dr Benaim will be responsible for leading Rexahn's clinical development programs, and providing strategic and clinical guidance for the company. Most recently Dr Benaim was senior vice-president of regulatory affairs and chief medical officer of Berg Pharma.